The Oncology Institute, Inc. STLN
6.70 USD -0.24 (-3.46%)
At closeNov 5, 2026, 7:31 PM EST
5.72 -0.98 -14.63%
After hours · Nov 5, 7:31 PM ET
6.56 Day range 7.02
2.38 52-week range 7.05
- YTD
- +88.20%
- 1 year
- +63.81%
Financial health
Altman Z-Score
2.65 Grey zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
3 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
Rating
C2 / 5 overall
- DCF 1
- Return on Equity 5
- Return on Assets 1
- Debt / Equity 1
- P/E 1
- P/B 1
Valuation
P/E -10.7×
FY 2025 5y median -10.7× FY 2025
P/S 1.1×
FY 2025 5y median 1.1× FY 2025
P/B -34.1×
FY 2025 5y median -34.1× FY 2025
P/FCF -19.3×
FY 2025 5y median -19.3× FY 2025
EV/EBITDA -14.3×
FY 2025 5y median -14.3× FY 2025
EV/Sales 1.2×
FY 2025 5y median 1.2× FY 2025
FCF Yield -5.2%
FY 2025 5y median -5.2% FY 2025
Profitability
Gross Margin 15.2%
FY 2025 5y median 15.2% FY 2025
Operating Margin -7.2%
FY 2025 5y median -7.2% FY 2025
Net Margin -12.1%
FY 2025 5y median -12.1% FY 2025
ROE 385.5%
FY 2025 5y median 385.5% FY 2025
ROIC -35.7%
FY 2025 5y median -35.7% FY 2025
ROA -36.8%
FY 2025 5y median -36.8% FY 2025
Growth (YoY)
Revenue 0.0%
FY 2025 FY 2025
Operating Income 0.0%
FY 2025 FY 2025
EPS (diluted) 0.0%
FY 2025 FY 2025
Free Cash Flow 0.0%
FY 2025 FY 2025
Financial Health
Current Ratio 1.6×
FY 2025 5y median 1.6× FY 2025
Quick Ratio 1.4×
FY 2025 5y median 1.4× FY 2025
Debt / Equity -6.6×
FY 2025 5y median -6.6× FY 2025
Net Debt / EBITDA -1.6×
FY 2025 5y median -1.6× FY 2025
Interest Coverage -3.2×
FY 2025 5y median -3.2× FY 2025
Dividends
Dividend Yield 0.0%
FY 2025 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2025 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31